← Back to Team

Kevin Pojasek

Venture Partner

$asset->title

Kevin joined SV in 2018 as a Venture Partner. He is President and Chief Executive Officer of Enara Bio, an SV-created company.

Prior to joining SV, Kevin was Chief Strategy and Business Officer and a member of the executive leadership team at Immunocore Ltd. In this role, he was responsible for shaping the Company’s corporate, R&D and growth strategies, as well as for overseeing business development. Kevin was also co-head of the Company’s Infectious Disease Unit and helped lead the Bill & Melinda Gates Foundation investment of up to $40m. Prior to joining Immunocore, Kevin was President, Chief Executive Officer of Quartet Medicine, a company he co-founded in late 2013 while working as an Entrepreneur-in-Residence at Atlas Ventures.

Kevin was also the Chief Operating Officer of Annovation Biopharma, which was sold to the Medicines Company in January 2015. He has also held senior executive R&D and corporate development roles at several biotech companies, including Vice President of Corporate Development at Kala Pharmaceuticals (NASDAQ:KALA) and, earlier in his career, spent time as an Investment Associate at PureTech Health (LSE: PRTC) an early stage venture capital firm.

Academic Credentials
PhD from the Biological Engineering Department at Massachusetts Institute of Technology; BA from the Molecular, Cellular and Developmental Biology Department at the University of Colorado, Boulder.

Portfolio

Investing in Women Code Logo
PROUD SIGNATORIES

We invest in talented innovators. We strongly adhere to the view that diversity, including under-represented groups, strongly adds to success. If you are an entrepreneur seeking investment and a partner who can help you to build your business, we would love to hear from you. Please get in contact with our team.